trending Market Intelligence /marketintelligence/en/news-insights/trending/EuFILqaspI84g3FeaWF4Iw2 content esgSubNav
In This List

Cutera laser platform gets expanded US FDA approval

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Cutera laser platform gets expanded US FDA approval

Cutera Inc. said its enlighten laser platform received expanded approval from the U.S. Food and Drug Administration.

The platform, which is already approved to remove tattoos and treat benign pigmented lesions, can now be used to clear acne scars. Cutera branded the new application PICO Genesis FX.

Cutera noted a recent study where 97% of patients saw mild to moderate improvement in acne scars. There was also statistically significant improvement in skin radiance, smoothness, pigmentation, erythema and pore size.

The enlighten Laser Platform with PICO Genesis FX will be available in the first quarter of 2019, according to the company.

Brisbane, Calif.-based Cutera said acne affects about 650 million people, 40% of whom will have some form of acne scarring.